<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607994</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00051980</org_study_id>
    <nct_id>NCT03607994</nct_id>
  </id_info>
  <brief_title>Study of the Effects of HIRREM-SOP for Insomnia</brief_title>
  <official_title>Randomized Controlled Pilot Trial of HIRREM-SOP for Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior research studies have shown benefit for use of a technique called High-resolution,&#xD;
      relational, resonance-based, electroencephalic mirroring (HIRREM®), to reduce symptoms of&#xD;
      moderate to severe insomnia. HIRREM uses scalp sensors to monitor brain electrical activity,&#xD;
      and software algorithms translate selected brain frequencies into audible tones in real time.&#xD;
      Those tones (acoustic stimulation) are reflected back to participants via ear buds in as&#xD;
      little as four milliseconds, providing the brain an opportunity to self-adjust and balance&#xD;
      its electrical pattern.&#xD;
&#xD;
      The purpose of this research study is to determine the effects of HIRREM-SOP, an updated&#xD;
      version of this technology that is based on the HIRREM approach, but now includes new&#xD;
      hardware and software, a standardized series of HIRREM protocols, and a fixed number of&#xD;
      sessions. Adults over the age of 18 who have documented sleep trouble that place them in the&#xD;
      category of subthreshold (mild), moderate, or severe clinical insomnia as defined by the&#xD;
      Insomnia Severity Index, are eligible to participate in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM®) is a&#xD;
      closed-loop, allostatic, acoustic stimulation neurotechnology that uses software-guided&#xD;
      algorithmic analysis to identify and translate selected brain frequencies into audible tones&#xD;
      to support real-time self-optimization of brain activity. Prior research demonstrates that&#xD;
      the use of HIRREM is associated with reduced symptoms of insomnia, and traumatic stress and&#xD;
      anxiety, and improved autonomic cardiovascular regulation across heterogeneous cohorts.&#xD;
      HIRREM has been safe and well tolerated in about 500 people across six IRB-approved studies.&#xD;
      However, the current in-office HIRREM approach remains very operator dependent (extensive&#xD;
      Technologist education and experience) and takes a sizeable time commitment from the&#xD;
      participant (typically ten or more sessions of 90-120 minutes each). To reduce participant&#xD;
      time required, and operator dependence, while increasing scalability, a new generation of&#xD;
      hardware and software has been developed. While based on the same core technology and&#xD;
      algorithms to mirror brainwaves with audible tones, this includes the use of faster, 64-bit&#xD;
      processing architecture for faster feedback, the use of 4 sensors, and the use of standard&#xD;
      protocols, all done with eyes closed (HIRREM-SOP). Although only 2 sensors are active at a&#xD;
      time, applying 4 sensors, for which the software can switch from one pair to the other&#xD;
      automatically, cuts in half the number of sensor placement changes needed, with reduced&#xD;
      session time and interruptions. A modified placebo condition now includes random timing and&#xD;
      pitch of the tones, which have not been acoustically engineered. This pilot study will&#xD;
      evaluate feasibility of this standardized, enhanced approach, and the effectiveness of&#xD;
      blinding for the placebo condition in participants with symptoms of insomnia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Actual">March 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study will compare acoustic stimulation linked to brainwave activity (HIRREM-SOP, along with continued current care, BCC) with acoustic stimulation not linked to brainwave activity (NCC, along with continued current care). The participants in the NCC group with will offered the opportunity to crossover and receive a course of BCC at the end of their original participation.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ISI Score From V1 to V3</measure>
    <time_frame>Baseline, V2 (0-14 days after intervention completion), V3 (4-6 weeks following V2)</time_frame>
    <description>The severity of insomnia symptoms is measured using the ISI with each data collection visit. The ISI is a 7 question measure, with responses from 0-4 for each question, yielding scores ranging from 0-28. Higher scores indicate the strength of the insomnia severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Believe They Are Receiving HIRREM-SOP</measure>
    <time_frame>Baseline, before Session 5, V2 (0-14 days after intervention completion), V3 (4-6 weeks following V2)</time_frame>
    <description>The participant will indicate which arm of the intervention they believe they are receiving. The effectiveness will be evaluated based on the expectation measure regarding group assignment prior to the 5th session.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Insomnia</condition>
  <condition>Sleep Deprivation</condition>
  <arm_group>
    <arm_group_label>HIRREM-SOP (BCC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acoustic stimulation linked to brainwave activity and continued current care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nonspecific acoustic stimulation (NCC)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HIRREM-SOP</intervention_name>
    <description>HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
    <arm_group_label>HIRREM-SOP (BCC</arm_group_label>
    <arm_group_label>nonspecific acoustic stimulation (NCC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NCC</intervention_name>
    <description>Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
    <arm_group_label>nonspecific acoustic stimulation (NCC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical Insomnia (Insomnia Severity Index ≥ 8) persisting by self-report for at least&#xD;
             a month&#xD;
&#xD;
          -  Subjects must have the ability to comply with basic instructions and be able to&#xD;
             comfortably sit still with the sensor leads attached&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable, unwilling, or incompetent to provide informed consent&#xD;
&#xD;
          -  Physically unable to come to the study visits, or to sit in a chair for several hours&#xD;
&#xD;
          -  Known seizure disorder&#xD;
&#xD;
          -  Known obstructive sleep apnea&#xD;
&#xD;
          -  Diagnosed periodic limb movement disorder or known restless legs syndrome&#xD;
&#xD;
          -  Known urinary problem (i.e. benign prostatic hypertrophy) which is the likely cause of&#xD;
             the sleep disturbance&#xD;
&#xD;
          -  Severe hearing impairment (because the subject will be using ear buds during&#xD;
             HIRREM-SOP)&#xD;
&#xD;
          -  Ongoing need for treatment with opiate, benzodiazepine, or anti-psychotic medications,&#xD;
             anti-depressant medications (SSRI, or SNRI's), sleep medications such as zolpidem or&#xD;
             eszopiclone, stimulants such as Adderall, Provigil, or Ritalin, or thyroid hormone&#xD;
&#xD;
          -  Anticipated and ongoing use of recreational drugs, alcohol, or energy drinks&#xD;
&#xD;
          -  Weight is over the chair limit (285 pounds)&#xD;
&#xD;
          -  Currently in another active intervention research study&#xD;
&#xD;
          -  Previous history of receiving or using HIRREM, BWO, HIRREM-SOP, or the wearable B2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles H Tegeler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <results_first_submitted>April 5, 2021</results_first_submitted>
  <results_first_submitted_qc>May 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 22, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurotechnology</keyword>
  <keyword>Autonomic Dysregulation</keyword>
  <keyword>Hyperarousal</keyword>
  <keyword>Brain Electrical Activity</keyword>
  <keyword>Closed-loop</keyword>
  <keyword>Acoustic Stimulation</keyword>
  <keyword>Allostasis</keyword>
  <keyword>Insomnia</keyword>
  <keyword>HIRREM-SOP</keyword>
  <keyword>Sleep Deprivation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Sleep Deprivation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03607994/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03607994/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HIRREM-SOP (BCC)</title>
          <description>Acoustic stimulation linked to brainwave activity and continued current care.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
        </group>
        <group group_id="P2">
          <title>Nonspecific Acoustic Stimulation (NCC)</title>
          <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.&#xD;
NCC: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued intervention (started sessions and dropped out due to time commitment and schedule)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>HIRREM-SOP (BCC)</title>
          <description>Acoustic stimulation linked to brainwave activity and continued current care.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
        </group>
        <group group_id="B2">
          <title>Nonspecific Acoustic Stimulation (NCC)</title>
          <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.&#xD;
NCC: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="7.96"/>
                    <measurement group_id="B2" value="54.67" spread="19.19"/>
                    <measurement group_id="B3" value="56.45" spread="14.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insomnia Severity Index (ISI)</title>
          <description>The ISI is a 7 question, self-reported measure to evaluate symptoms of insomnia, with responses from 0-4 for each question, yielding scores ranging from 0-28. Lower scores represent better outcomes. The primary outcome will be change from enrollment to 4-6 weeks after completion of the intervention.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.90" spread="4.65"/>
                    <measurement group_id="B2" value="18.00" spread="3.07"/>
                    <measurement group_id="B3" value="16.59" spread="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration with Sleep Trouble</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.98" spread="11.43"/>
                    <measurement group_id="B2" value="5.28" spread="3.89"/>
                    <measurement group_id="B3" value="6.96" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in ISI Score From V1 to V3</title>
        <description>The severity of insomnia symptoms is measured using the ISI with each data collection visit. The ISI is a 7 question measure, with responses from 0-4 for each question, yielding scores ranging from 0-28. Higher scores indicate the strength of the insomnia severity.</description>
        <time_frame>Baseline, V2 (0-14 days after intervention completion), V3 (4-6 weeks following V2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIRREM-SOP (BCC)</title>
            <description>Acoustic stimulation linked to brainwave activity and continued current care.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
          </group>
          <group group_id="O2">
            <title>Nonspecific Acoustic Stimulation (NCC)</title>
            <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.&#xD;
NCC: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ISI Score From V1 to V3</title>
          <description>The severity of insomnia symptoms is measured using the ISI with each data collection visit. The ISI is a 7 question measure, with responses from 0-4 for each question, yielding scores ranging from 0-28. Higher scores indicate the strength of the insomnia severity.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.27" spread="1.55"/>
                    <measurement group_id="O2" value="-4.69" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Believe They Are Receiving HIRREM-SOP</title>
        <description>The participant will indicate which arm of the intervention they believe they are receiving. The effectiveness will be evaluated based on the expectation measure regarding group assignment prior to the 5th session.</description>
        <time_frame>Baseline, before Session 5, V2 (0-14 days after intervention completion), V3 (4-6 weeks following V2)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIRREM-SOP (BCC)</title>
            <description>Acoustic stimulation linked to brainwave activity and continued current care.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
          </group>
          <group group_id="O2">
            <title>Nonspecific Acoustic Stimulation (NCC)</title>
            <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.&#xD;
NCC: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Believe They Are Receiving HIRREM-SOP</title>
          <description>The participant will indicate which arm of the intervention they believe they are receiving. The effectiveness will be evaluated based on the expectation measure regarding group assignment prior to the 5th session.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Guessed BCC Group (Before Session 5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Guessed NCC Group (Before Session 5)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16-18 weeks after completion of the intervention.</time_frame>
      <desc>No adverse events or serious adverse events documented during study. Participant ST06 did mention unusual symptoms that was documented, but unsure if study related due to stopping meditation and marijuana use, which were both daily occurrences, as well as a diet change. ST06 reported that she does not feel that the sessions caused her issues.</desc>
      <group_list>
        <group group_id="E1">
          <title>HIRREM-SOP (BCC)</title>
          <description>Acoustic stimulation linked to brainwave activity and continued current care.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.</description>
        </group>
        <group group_id="E2">
          <title>Nonspecific Acoustic Stimulation (NCC)</title>
          <description>Continued current care and acoustic stimulation that is not linked to brainwave activity.&#xD;
HIRREM-SOP: HIRREM-SOP is an updated version of HIRREM. It is a novel, noninvasive, closed-loop, brainwave mirroring, acoustic stimulation neurotechnology to support relaxation and auto-calibration of neural oscillations, using auditory tones to reflect brain frequencies in near real time.&#xD;
NCC: Nonspecific acoustic stimulation with randomly generated tones not linked to brain activity.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Reported &quot;constant whooshing in ears, pulse in the 80's, and increased hot flashes.&quot; ST06 stopping meditation and marijuana use, both daily occurrences, as well as diet change. ST06 stated she did not feel that the sessions caused her issues.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As a pilot study, small sample size was the key limiting factor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Catherine Tegeler - Project Manager</name_or_title>
      <organization>Wake Forest Baptist Health</organization>
      <phone>336-716-9341</phone>
      <email>categele@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

